RenovoRx, Inc. - Common Stock (OQ:RNXT)
Business Focus: N/A
May 14, 2024 09:00 am ET
RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai, Chief Executive Officer, will participate in a fireside chat at Alliance Global Partners (A.G.P.) Virtual Healthcare
Apr 18, 2024 08:30 am ET
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that, in light of its recent successful fundraising activity, it has received written confirmation from The Nasdaq Stock Market LLC (“Nasdaq”)
Apr 16, 2024 08:30 am ET
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today highlights a presentation of a clinical data abstract at t
Apr 15, 2024 08:00 am ET
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the closing of its previously announced private placement of approximately $11.1 million in gross proceeds.
Apr 08, 2024 08:30 am ET
RenovoRx Announces $11.1 Million at Market Private Placement
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the execution of definitive subscription agreements with accredited investors for a private placement which is expected to resu
Apr 05, 2024 08:30 am ET
RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai, RenovoRx’s Chief Executive Officer, will present at the Canaccord Genuity 2024 Horizons in Oncology Virtual Conferenc
Mar 12, 2024 09:00 am ET
RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai, RenovoRx’s Chief Executive Officer, will present at the 36th Annual ROTH Conference to be held March 17-19, 2024 in D
Mar 08, 2024 04:05 pm ET
RenovoRx Highlights Key Leadership Promotions
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today highlighted the recent key leadership promotions of Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak, CPA to Principal Accounting Offic
Feb 06, 2024 08:30 am ET
RenovoRx CEO Issues Letter to Shareholders
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from Chief Executive Officer, Shaun Bagai.
Jan 29, 2024 08:30 am ET
RenovoRx Closes $6.1 Million Private Placement
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that it has closed a private placement (the “private placement” or the “financing”) resulting in gross proceeds of approximately $6.1 million, be
Dec 21, 2023 08:30 am ET
RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the expansion of their clinical development pipeline in preparation for the commencement of a second Phase III trial. The CouGar Trial will evaluate
Dec 19, 2023 08:30 am ET
RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
RenovoRx, Inc. (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the acceptance of a clinical data abstract for the
Dec 13, 2023 08:31 am ET
RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform
RenovoRx, Inc. (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that the Company has filed an international patent application under the Patent Cooperation Treaty (PCT) for its novel Trans-Arterial Micro-Perfusion (TAMP) therapy platform.
Nov 16, 2023 08:35 am ET
RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company’s Scientific Advisory Board (SAB). Dr. Ducreux is the Head of the Gastrointestinal Oncology Unit and Gastrointestinal Oncolo
Nov 14, 2023 08:30 am ET
RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the third quarter ended September 30, 2023.
Oct 02, 2023 08:30 am ET
RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that CEO, Shaun Bagai, will present at the
Aug 17, 2023 08:30 am ET
RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the second quarter ended June 30, 2023.
Jul 31, 2023 08:30 am ET
RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that its CEO Shaun Bagai will provide a corporate overview and update at the 43rd Annual Canaccord Genuity Growth Conference on Thursday, August 10, 2023 at 10:30 AM ET in Boston, MA
Jul 20, 2023 08:00 am ET
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
RenovoRx, Inc. (“RenovoRx”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, and
Jun 29, 2023 08:00 am ET
RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today presented new positive data on progression-free survival (PFS) from the pivotal Phase III open label TIGeR-PaC study of RenovoGem (intra-arterial administration of gemcitabine) in locally advanced pancr
Jun 20, 2023 08:30 am ET
RenovoRx Appoints Margaret A. Tempero, M.D., to Scientific Advisory Board
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Margaret A. Tempero, M.D., Director, UCSF Pancreas Center and Leader of the UCSF Pancreas Cancer Program, to the Company’s Scientific Advisory Board (SAB).
Jun 12, 2023 08:30 am ET
RenovoRx Announces ROTH Capital Key Opinion Leader (KOL) Webcast on June 15
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that ROTH Capital will host a Key Opinion Leader (KOL) webcast with Dr. Michael Pishvaian, Principal Investigator of the Phase III TIGeR-PaC clinical trial and Director of the Gastrointestinal,
Jun 01, 2023 08:30 am ET
RenovoRx Initiates Patient Enrollment at University of Texas Southwestern Medical Center for Pivotal Phase III TIGeR-PaC Clinical Trial
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that the University of Texas (UT) Southwestern Medical Center is now enrolling pancreatic cancer patients in the open label, randomized Phase III TIGeR-PaC clinical trial. The study is investig
May 25, 2023 08:30 am ET
RenovoRx Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the acceptance of a late-breaking oral presentation for its lead product candidate RenovoGem, in the treatment of locally advanced pancreatic cancer (LAPC), at the upcoming ESMO World Congress
May 24, 2023 08:30 am ET
RenovoRx to Present at the LD Micro Invitational XIII Conference
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of cancers, today announced that Shaun Bagai, CEO, will present at the 13th Annual LD Micro Invitational, held on June 6-8, 2023 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.
May 15, 2023 08:30 am ET
RenovoRx Reports First Quarter 2023 Financial Results and Operational Highlights
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of cancers, today announced financial results for the first quarter ended March 31, 2023.
May 01, 2023 08:30 am ET
RenovoRx Sponsors Pancreatic Cancer Action Network’s PurpleStride® Event
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced it joined
Apr 28, 2023 08:30 am ET
RenovoRx to Participate in the Aegis Capital Virtual Conference on May 3, 2023
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced that Shaun Bagai, CEO of RenovoRx, will present at the Aegis Capital Virtual Conference on May 3rd at 3:30 p.m. ET. The online presentation can be accessed here.
Apr 27, 2023 08:30 am ET
RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on targeted drug-delivery with an initial application in locally advanced pancreatic cancer (LAPC), announced today that Robert J. Spiegel, MD, has been appointed to the Company’s Board of Directors, effective April 25, 2023.
Apr 14, 2023 08:30 am ET
RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced that Poster #CT084 is presenting detailed, open label, Phase III TIGeR-PaC study interim data analysis of its innovative RenovoGem therapy for pancreatic cancer patients at the American Association for Cancer Research (AACR) Annual Meeting, on Monday, April 17, 2023, at 9:00 AM ET in Orlando, Florida. AACR is underway through Wednesday, April 19, 2023.
Apr 11, 2023 08:30 am ET
RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced today that Leesa Gentry has joined the Company as Senior Vice President of Clinical Operations. Ms. Gentry, an industry expert in clinical trials management, brings the RenovoRx team valuable leadership experience to further advance studies in cancer treatment. In the past year, Ms. Gentry is the fourth addition to the Company’s executive management team following COO, Angela Gill Nelms, CFO, James Ahlers, and Vice President and Controller, Ron
Mar 30, 2023 12:20 pm ET
RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
RenovoRx, Inc. (the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 1,557,632 shares of the Company’s common stock (or common stock equivalents) at a purchase price of $3.21 per share of common stock (or common stock equivalent) in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about April 3, 2023, subject to t
Mar 30, 2023 08:30 am ET
RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced that it will present detailed, open label, planned Phase III interim data analysis of its innovative RenovoGem therapy for pancreatic cancer patients at the American Association for Cancer Research (AACR) Annual Meeting on April 17, 2023 in Orlando, Florida.
Mar 08, 2023 08:30 am ET
RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGemTM as a Treatment Option for Locally Advanced Pancreatic Cancer
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced promising interim data in the Phase III open label TIGeR-PaC clinical trial. The study is investigating the Company’s first product candidate, RenovoGem, as a potential treatment option in locally advanced pancreatic cancer (“LAPC”).
Mar 02, 2023 08:30 am ET
RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today is reporting its financial results for the year ended December 31, 2022, and a pipeline update including the status of the interim analysis of for the Company’s Phase III TIGeR-PaC clinical trial.
Mar 01, 2023 08:30 am ET
RenovoRx to Present at the 35th Annual Roth Conference on March 13, 2023
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announces that Shaun Bagai, Chief Executive Officer, will be presenting at the 35th Annual Roth Conference, to be held March 12-14, 2023, in Dana Point, California. To register for the event, visit the
Jan 25, 2023 08:30 am ET
RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced that Shaun Bagai, Chief Executive Officer, is scheduled to present virtually at the Sequire Biotechnology Conference on Thursday, February 2, 2023 at 4 p.m. (ET). To register for the event, visit the Sequire Biotechnology Conference
Jan 18, 2023 08:30 am ET
RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and De
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced initial results from a pharmacokinetic (PK) substudy within the phase III un-blinded randomized control TIGeR-PaC clinical trial to be presented at the 2023 ASCO Gastrointestinal (ASCO GI) Cancers Symposium this week. The TIGeR-PaC clinical trial is evaluating intra-arterial (IA) administration of gemcitabine (chemotherapy) using the proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) platform for targeted treatment of Locally Advanced Pancreatic Cancer (L
Jan 05, 2023 08:30 am ET
RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US Patent
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors, today announced that on January 3, 2023 the United States Patent and Trademark Office issued US patent number 11,541,211 broadly covering methods for treating cholangiocarcinoma (bile duct cancer) by selectively delivering one or more therapeutic agents into targeted regions of the bile duct. This is RenovoRx’s eighth US patent.
Dec 15, 2022 08:30 am ET
RenovoRx Announces Acceptance of Four Clinical Data Abstracts at the 2023 ASCO Gastrointestinal Cancers (ASCO GI) Symposium
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors, today announced the acceptance of four clinical data abstracts supporting its lead oncology product candidate, RenovoGem, and its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy platform to be presented at the 2023 ASCO Gastrointestinal Cancers Symposium (ASCO GI). The Symposium is to be held on January 19-21, 2023 in San Francisco, California and online.
Nov 17, 2022 08:30 am ET
RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP® Therapy Platform for Targeted Treatment of Cancers
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy platform, today announced RenovoTAMP was highlighted in two presentations delivered at the Advanced Interventional Management Symposium (AIMsymposium). RenovoTAMP is a unique therapy platform designed for targeted intra-arterial (IA) delivery of chemotherapy directly to tumors. This symposium was the 30th annual AIMsymposium and is being held November 14-17, 2022 at the Ne
Nov 14, 2022 08:30 am ET
RenovoRx Reports Third Quarter 2022 Financial Results
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP®) therapy platform, today reported its financial results for the quarter ended September 30, 2022.
Oct 21, 2022 08:30 am ET
RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ET
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP®) therapy platform, today announced that the Company’s CEO, Shaun Bagai, will participate in a ROTH Capital Partners Deep Dive webinar on Thursday, October 27th at 1 p.m. ET. To register for the event please visit
Oct 04, 2022 08:00 am ET
RenovoRx to Participate in Upcoming October 2022 Investor Conferences
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP®) therapy platform, today announced management’s participation in two upcoming investor conferences this month. Conferences include ROTH Inaugural Healthcare Opportunities, October 6th, and LD Micro Main Event XV, October 25th-27th.
Sep 28, 2022 08:30 am ET
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology (CIO) Highlighting its Innovative Therapy Platform for Targeted Treatment of Pancreatic Cancer
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform, today announced Ripal Gandhi, M.D., FSIR, FSVM presented, “Trans-Arterial Micro-Perfusion Therapy for Pancreatic Cancer,” at the recent
Sep 19, 2022 08:30 am ET
RenovoRx Appoints Angela Gill Nelms as Chief Operating Officer
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform, today announced that Angela Gill Nelms has joined the company as Chief Operating Officer (“COO”).
Sep 07, 2022 08:00 am ET
RenovoRx to Participate in the H.C. Wainwright 24th Annual Global Investment Conference, September 12-14, 2022
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP™) therapy platform, today announced management’s participation in the upcoming H.C. Wainwright 24th Annual Global Investment Conference. This conference is to be held at the Lotte New York Palace Hotel in New York City on September 12-14, 2022.
Aug 15, 2022 08:00 am ET
RenovoRx Reports Second Quarter 2022 Financial Results
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform, today reported its financial results for the quarter ended June 30, 2022.
Jul 19, 2022 08:30 am ET
RenovoRx Appoints James Ahlers as Chief Financial Officer
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is announcing the appointment of James Ahlers as Chief Financial Officer (CFO), effective July 15, 2022, and the addition of Ronald B. Kocak as Vice President and Controller for RenovoRx. Mr. Ahlers replaces Christopher J. Lehman, who joined RenovoRx in connection with its initial public offering and is leaving to pursue a new business opportunity.
Jul 13, 2022 08:00 am ET
RenovoRx Launches “The RenovoRx Story” Video Series
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced the launch of a new video series – The RenovoRx Story. This video series provides viewers with a unique opportunity to learn more about the Company, its leadership team, and the innovative RenovoTAMP™ (RenovoRx Trans-Arterial Micro-Perfusion) therapeutic platform. Also, highlighted in the video series is the Company’s multi-center TIGeR-PaC Phase 3 clinical trial in locally advanced pancreatic cancer.
Jul 13, 2022 08:00 am ET
RenovoRx Launches “The RenovoRx Story” Video Series
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced the launch of a new video series – The RenovoRx Story. This video series provides viewers with a unique opportunity to learn more about the Company, its leadership team, and the innovative RenovoTAMP™ (RenovoRx Trans-Arterial Micro-Perfusion) therapeutic platform. Also highlighted in the video series is the Company’s multi-center TIGeR-PaC Phase 3 clinical trial in locally advanced pancreatic cancer. The video can be viewed here:
Jun 09, 2022 08:30 am ET
RenovoRx and TIGeR-PaC Leadership to Host RenovoTAMP™ Webinar on June 21, 2022
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that they will host a webinar highlighting their RenovoTAMP™ therapy platform. The webinar, “Facing Today’s Challenges in Pancreatic Cancer Treatment: Understanding RenovoRx’s Trans-Arterial Micro-Perfusion Therapy Platform,” will be held on Tuesday, June 21st at 8:00 am (ET). To register for this event, click
Jun 02, 2022 08:30 am ET
RenovoRx to Participate in the University of Cambridge’s Academy of Therapeutic Sciences Gateway to Translation Seminar Series on June 8, 2022
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that it will participate in the Gateway to Translation Webinar Series hosted by the University of Cambridge’s Academy of Therapeutic Sciences (CATS) on Wednesday, June 8, 2022 at 1:00 PM ET. Dr. Ramtin Agah, Chief Medical Officer and Co-Founder of RenovoRx, will present a seminar, “Localized Intra-arterial Drug Delivery for Treatment of Solid Tumors.” To register for this seminar, click
May 19, 2022 08:30 am ET
RenovoRx to Present Preclinical Research Data Demonstrating its Innovative Therapy Platform’s Potential Utility for the Treatment of Bile Duct Cancer
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announces that it will present preclinical research supporting its planned second clinical indication, bile duct cancer, also known as cholangiocarcinoma, at the
May 18, 2022 08:00 am ET
RenovoRx to Participate in Upcoming H.C Wainwright Global Investment Conference in May 2022
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced management’s participation in the H.C. Wainwright Global Investment Conference on May 23-26, 2022 in Miami Beach, Florida.
May 16, 2022 07:30 am ET
RenovoRx Reports First Quarter 2022 Financial Results
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is reporting its financial results for the quarter ended March 31, 2022.
Mar 30, 2022 08:30 am ET
RenovoRx Reports Full Year 2021 Financial Results
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is reporting its financial results for the year ended December 31, 2021.
Mar 11, 2022 08:30 am ET
RenovoRx to Participate in March 2022 Investor Conferences
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced its leadership’s participation in two upcoming Investor Conferences this month.
Feb 22, 2022 08:00 am ET
RenovoRx Enrolls First Pancreatic Cancer Patient at Columbia University’s New York-Presbyterian Hospital Irving Medical Center in Ongoing TIGeR-PaC Phase 3 Clinical Trial
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced enrollment of its first patient at one of its newest clinical sites, Columbia University New York-Presbyterian Hospital Irving Medical Center (“Columbia University”), in its ongoing TIGeR-PaC Phase 3 clinical trial. The study is evaluating the Company’s therapy platform RenovoTAMP™ (RenovoRx Trans-Arterial Micro-Perfusion), as a potential treatment option for locally advanced pancreatic cancer (“LAPC”) that may extend life while improving quality of
Feb 03, 2022 09:29 am ET
RenovoRx to Host “Delivering Therapy Where it Matters” Fireside Chat with CEO, Shaun Bagai, on February 23rd at 12 P.M. ET
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, will host the “Delivering Therapy Where it Matters” fireside chat with CEO, Shaun Bagai, on Wednesday, February 23rd at 12 p.m. ET.
Jan 19, 2022 08:00 am ET
RenovoRx Announces Presentation at the 2022 SPECTRUM Conference Highlighting Its Innovative RenovoTAMP™ Therapy for Targeted Treatment of Cancer
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that Dr. Ripal Gandhi, M.D., FSIR, FSVM, a Principal Investigator in the Company’s Phase 3 TIGeR-PaC study, presented ‘Trans-arterial Treatment Option in Pancreas Cancer’ at the recent 2022 S
Jan 06, 2022 08:00 am ET
RenovoRx to Present at the H.C. Wainwright Bioconnect Virtual Conference
RenovoRx, Inc. (NASDAQ: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that Shaun Bagai, Chief Executive Officer, will participate in the H.C. Wainwright Bioconnect Virtual Conference on behalf of RenovoRx. The conference will be held January 10-13, 2022.
Nov 15, 2021 04:15 pm ET
RenovoRx Announces Third Quarter 2021 Financial Results
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today reported its unaudited financial results for the third quarter ended September 30, 2021.
Nov 11, 2021 06:00 am ET
RenovoRx Announces Presentation of Final Data from RR2 Observational Registry Study at 2021 Pancreas Club Annual Meeting
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that it will be presenting an ePoster at the 2021 Pancreas Club Annual Meeting being held virtually on November 11-12, 2021.
Nov 10, 2021 08:31 am ET
Thinking about buying stock in RenovoRx, Roblox, Fubotv, Unity Biotechnology, or FibroGen?
NEW YORK, Nov. 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RNXT, RBLX, FUBO, UBX, and FGEN.
Nov 09, 2021 06:00 am ET
Presentation During New Advances in the Management of Pancreatic Cancer Course Highlights Intra-Arterial Chemotherapy as a Potential Innovative Treatment for Pancreatic Cancer
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced its novel therapy platform, RenovoTAMPTM (RenovoRx Trans-Arterial Micro-Perfusion), will be highlighted during a presentation by expert panelist, Dr. Ripal Gandhi, at the Miami Cancer Institute’s New Advances in the Management of Pancreatic Cancer CME course this evening.
Sep 07, 2021 06:00 am ET
RenovoRx Receives New 510(k) Clearance for its RenovoCath® Delivery System Designed for Targeted Treatment of Solid Tumors
LOS ALTOS, Calif., Sept. 7, 2021 /PRNewswire/ -- RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary RenovoCath Delivery System. The RenovoCath Delivery System is the device component of the Company's initial product, RenovoGem™. This drug/device combination used in RenovoRx's Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy platform is a dual-balloon infusion catheter delivering chemotherapy directly to tumors via art
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.